Cargando…

Nanotechnology-Based Approach in Tuberculosis Treatment

Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasiruddin, Mohammad, Neyaz, Md. Kausar, Das, Shilpi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/
https://www.ncbi.nlm.nih.gov/pubmed/28210505
http://dx.doi.org/10.1155/2017/4920209
_version_ 1782504891292319744
author Nasiruddin, Mohammad
Neyaz, Md. Kausar
Das, Shilpi
author_facet Nasiruddin, Mohammad
Neyaz, Md. Kausar
Das, Shilpi
author_sort Nasiruddin, Mohammad
collection PubMed
description Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.
format Online
Article
Text
id pubmed-5292193
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-52921932017-02-16 Nanotechnology-Based Approach in Tuberculosis Treatment Nasiruddin, Mohammad Neyaz, Md. Kausar Das, Shilpi Tuberc Res Treat Review Article Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB. Hindawi Publishing Corporation 2017 2017-01-22 /pmc/articles/PMC5292193/ /pubmed/28210505 http://dx.doi.org/10.1155/2017/4920209 Text en Copyright © 2017 Mohammad Nasiruddin et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nasiruddin, Mohammad
Neyaz, Md. Kausar
Das, Shilpi
Nanotechnology-Based Approach in Tuberculosis Treatment
title Nanotechnology-Based Approach in Tuberculosis Treatment
title_full Nanotechnology-Based Approach in Tuberculosis Treatment
title_fullStr Nanotechnology-Based Approach in Tuberculosis Treatment
title_full_unstemmed Nanotechnology-Based Approach in Tuberculosis Treatment
title_short Nanotechnology-Based Approach in Tuberculosis Treatment
title_sort nanotechnology-based approach in tuberculosis treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/
https://www.ncbi.nlm.nih.gov/pubmed/28210505
http://dx.doi.org/10.1155/2017/4920209
work_keys_str_mv AT nasiruddinmohammad nanotechnologybasedapproachintuberculosistreatment
AT neyazmdkausar nanotechnologybasedapproachintuberculosistreatment
AT dasshilpi nanotechnologybasedapproachintuberculosistreatment